Evidence Hub

Severe Pulmonary Arterial Hypertension Induced by Dasatinib in a Patient with Chronic Myeloid Leukemia: A Case Report

S. Hamady, Boucetta Abdullah, Obeidat Saleh, M. Haboub, Rachida Haball

Cardiology and Angiology An International Journal, 2025

Abstract

Pulmonary arterial hypertension (PAH) is a rare but recognized adverse effect of tyrosine kinase inhibitors, notably Dasatinib, prescribed in chronic myeloid leukemia (CML). Due to potential reversibility, prompt recognition and management are essential.

We report a 60-year-old male receiving Dasatinib for CML who presented with NYHA class IV dyspnea. Echocardiography showed severe right ventricular dilation and elevated pulmonary pressures. Right heart catheterization confirmed precapillary PAH. Other causes were ruled out. Following discontinuation of Dasatinib and initiation of combination PAH-specific therapy (epoprostenol, bosentan, tadalafil), the patient demonstrated clinical and hemodynamic improvement.This case highlights the need for vigilance in patients on Dasatinib, especially when respiratory symptoms arise. Early intervention can improve outcomes in drug-induced PAH.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free